Peripheral endothelial dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome.
Scherbakov, Nadja, Szklarski, Marvin, Hartwig, Jelka et al. · ESC heart failure · 2020 · DOI
Quick Summary
This study looked at blood vessel function in people with ME/CFS by measuring how well small arteries in the arm respond to increased blood flow. Researchers found that about half of ME/CFS patients had abnormal blood vessel responses, compared to only 20% of healthy people. People with this blood vessel problem reported more severe fatigue, more frequent need for rest breaks, and worse immune-related symptoms like sore throat and swollen lymph nodes.
Why It Matters
Endothelial dysfunction is an established cardiovascular risk factor; identifying it in over half of ME/CFS patients suggests a potential mechanism linking ME/CFS to vascular complications and may explain symptoms like orthostatic intolerance. This finding opens investigation into whether treating vascular dysfunction could improve ME/CFS outcomes and reduce long-term cardiovascular risk in this population.
Observed Findings
Peripheral endothelial dysfunction present in 51% of ME/CFS patients versus 20% of healthy controls
Patients with ED reported more severe disease (Bell score 31±12 vs 40±16) and greater fatigue symptoms requiring more frequent breaks
ED correlated with immune-associated symptoms including sore throat and painful lymph nodes
Five of six patients with ED who received immunoadsorption showed endothelial function improvement over 12 months
No differences in inflammatory markers (sVCAM, sICAM) between ED and non-ED patient groups
Inferred Conclusions
Peripheral endothelial dysfunction is a frequent and significant pathophysiological feature in ME/CFS, associated with disease severity and immune symptom burden
The improvement in endothelial function following immunoadsorption in a subset of patients suggests a potential immune-mediated mechanism underlying ED in ME/CFS
Endothelial dysfunction in ME/CFS may represent an important cardiovascular risk factor warranting further investigation and potential clinical monitoring
Remaining Questions
Does peripheral endothelial dysfunction precede ME/CFS development, or does it develop secondary to the disease?
Do ME/CFS patients with endothelial dysfunction experience increased cardiovascular morbidity and mortality compared to those without ED?
What This Study Does Not Prove
This study cannot prove that endothelial dysfunction causes ME/CFS severity or that it directly causes cardiovascular disease in ME/CFS patients—only that the two are associated. The small immunoadsorption subgroup (n=6) limits conclusions about whether treating immune dysfunction improves endothelial function. Cross-sectional design prevents determination of whether ED develops before, during, or after ME/CFS onset.
What specific immune mechanisms drive endothelial dysfunction in ME/CFS, and can immunotherapies beyond the tested immunoadsorption improve vascular function?
Does treatment of endothelial dysfunction improve ME/CFS symptom severity and functional capacity?